Alnylam Pharmaceuticals, Inc. vs Lululemon Athletica Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288.06 (market cap $39.89B), while Lululemon Athletica Inc trades at $120.06 (market cap $13.54B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.9× Lululemon Athletica Inc's market cap. Which is the better fit depends on your goals.
| ALNY | LULU | |
|---|---|---|
Market Cap | $39.89B | $13.54B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $236.51 |
52-Week Low | $278.09 | $105.43 |
Enterprise Value | $38.15B | $14.16B |
Trailing returns across standard periods
Latest headlines on both assets
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →